Literature DB >> 33038589

Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis.

Roselie Achten1, Daphne Bakker2, Lieneke Ariens2, Amanda Lans2, Judith Thijs2, Jorien van der Schaft2, Joke de Boer3, Deepak Balak2, Marlies de Graaf2, Chantal van Luijk3, Marjolein de Bruin-Weller2.   

Abstract

Entities:  

Year:  2020        PMID： 33038589     DOI： 10.1016/j.jaip.2020.09.042

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  6 in total

1.  Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.

Authors:  Roselie E Achten; Chantal Van Luijk; Lisa Van der Rijst; Daphne Bakker; Lotte Spekhorst; Nicolaas Zuithoff; Marie Schuttelaar; Geertruida Romeijn; Angelique Voorberg; Marijke Kamsteeg; Inge Haeck; Marlies De Graaf; Judith Thijs; Joke De Boer; Marjolein De Bruin-Weller
Journal:  Acta Derm Venereol       Date:  2022-03-11       Impact factor: 3.875

2.  Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series.

Authors:  Mélanie Hébert; Susan Ruyu Qi; Eunice You; Mathieu Mercier; Patricia-Ann Laughrea
Journal:  BMJ Open Ophthalmol       Date:  2022-05

Review 3.  Type 2 immunity-driven diseases: Towards a multidisciplinary approach.

Authors:  Dorian Hassoun; Olivier Malard; Sébastien Barbarot; Antoine Magnan; Luc Colas
Journal:  Clin Exp Allergy       Date:  2021-10-15       Impact factor: 5.401

Review 4.  A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  JID Innov       Date:  2021-07-30

5.  Clinical Characteristics and Treatment for Dupilumab-Related Ocular Complications in Atopic Dermatitis Patients.

Authors:  Zujaja Tauqeer; Stephanie E Jinno; Caroline W Chung; Mina Massaro-Giordano; Vatinee Y Bunya
Journal:  Clin Ophthalmol       Date:  2022-03-29

6.  Ocular surface disease is common in moderate-to-severe atopic dermatitis patients.

Authors:  Roselie E Achten; Daphne S Bakker; Chantal M van Luijk; Marlot van der Wal; Marlies de Graaf; Femke van Wijk; Nicolaas P A Zuithoff; Lisa P van der Rijst; Celeste M Boesjes; Judith L Thijs; Joke H de Boer; Marjolein S de Bruin-Weller
Journal:  Clin Exp Allergy       Date:  2022-03-18       Impact factor: 5.401
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.